ViCentra announced today that it appointed Ian Wells as its new CFO and added Thomas A. West to its board of directors.
Wells’ appointment went into effect on June 19, 2026, while West became an independent director on July 1, 2026.
The Utrecht, the Netherlands-based automated insulin delivery system developer said the appointments lay the financial and governance foundation for its plans to scale across Europe and enter the U.S. market. The company recently scaled up manufacturing as well to accommodate the expected demand for its insulin delivery technology.
ViCentra develops the Kaleido insulin patch pump system, which recently launched in Germany alongside the Dexcom G7 and Diabeloop DBLG2.
The miniature pump offers users options in terms of wearability and comes with two durable, rechargeable pumps, eliminating the need to dispose of the pump every three days, while the infusion set lasts for that three-day span. Rather than a traditional syringe pump setup, Kaleido has a micro-pumping chamber that uses valves alongside a unique blockage detection system.
More about the new appointments
Wells joins ViCentra after most recently serving as global CFO at Hoya Vision Care. There, he led significant margin expansion, multiple acquisitions, and a global finance transformation across a team of more than 500.
He brings nearly two decades of finance leadership in medtech, with ViCentra saying that he offers the capital-markets discipline required to support its next phase of growth and financing.
West, meanwhile, brings a combination of public-company leadership and experience in the diabetes sector and medtech. Most recently, he served as president, CEO and director of Nalu Medical, which Boston Scientific acquired for $600 million this year.
Before Nalu, West served as president, CEO and director of Intersect ENT, leading it through a $1.1 billion acquisition by Medtronic in 2022.
Earlier in his career, West spend more than two decades at Johnson & Johnson. His stint included leadership roles as worldwide VP of strategy and business development for J&J’s family of diabetes companies and division president of LifeScan in North America and EMEA.
ViCentra said its appointments position it to accelerate adoption beyond its current base of more than 5,000 users in Germany, the Netherlands and France. It hopes to expand into additional U.S. markets as it prepares for U.S. market entry.
Commentary from ViCentra leadership and the new appointments
Tom Arnold, ViCentra CEO, said:
“Ian and Tom’s appointments further strengthen the leadership team that we have assembled to support our next stage of growth. Following the successful scale-up of our commercial manufacturing capabilities and continued improvements in unit economics, we are well positioned to build on this momentum. Their deep financial, strategic and operational expertise will be invaluable as we accelerate our expansion across Europe and prepare for entry in the U.S market. These appointments mark another important step in building a company poised to lead the future of diabetes care.”
Wells said:
“Kaleido addresses a clear and growing need in diabetes care, and ViCentra has built strong commercial momentum. My focus is on strengthening the financial foundation of the business to support scalable growth, disciplined capital allocation, and long-term value creation, ultimately enabling access for more people living with diabetes.”
West said:
“ViCentra has developed a highly differentiated insulin delivery system and built strong momentum in a market I know well. The combination of a design-led system, a proven algorithm, and commercial-scale manufacturing is what it takes to build a category leader. I am glad to join the Board and help the team create lasting value for patients and shareholders as it scales in Europe and enters the United States.”
